✦ LIBER ✦

The “Final” 5-Year Follow-Up From the ENDEAVOR IV Trial Comparing a Zotarolimus-Eluting Stent With a Paclitaxel-Eluting Stent

✍ Scribed by Kirtane, Ajay J.; Leon, Martin B.; Ball, Michael W.; Bajwa, Harpaul S.; Sketch, Michael H.; Coleman, Patrick S.; Stoler, Robert C.; Papadakos, Stylianos; Cutlip, Donald E.; Mauri, Laura; Kandzari, David E.

Book ID: 123068774
Publisher: American College of Cardiology
Year: 2013
Tongue: English
Weight: 487 KB
Volume: 6
Category: Article
ISSN: 1936-8798
DOI: 10.1016/j.jcin.2012.12.123

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

TCT-24: The “Final” Five-Year Follow-up

TCT-24: The “Final” Five-Year Follow-up from the ENDEAVOR IV Trial Comparing a Zotarolimus-Eluting Stent with a Paclitaxel-Eluting Stent

📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 274 KB

Final 5-Year Outcomes From the Endeavor

Final 5-Year Outcomes From the Endeavor Zotarolimus-Eluting Stent Clinical Trial Program

✍ Kandzari, David E.; Leon, Martin B.; Meredith, Ian; Fajadet, Jean; Wijns, Willia 📂 Article 📅 2013 🏛 American College of Cardiology 🌐 English ⚖ 490 KB

Improved Late Clinical Safety With Zotar

Improved Late Clinical Safety With Zotarolimus-Eluting Stents Compared With Paclitaxel-Eluting Stents in Patients With De Novo Coronary Lesions: 3-Year Follow-Up From the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) Trial

✍ Martin B. Leon; Eugenia Nikolsky; Donald E. Cutlip; Laura Mauri; Henry Liberman; 📂 Article 📅 2010 🏛 American College of Cardiology 🌐 English ⚖ 557 KB

TCT-404: Late Safety and Efficacy of a Z

TCT-404: Late Safety and Efficacy of a Zotarolimus-Eluting Stent Compared with a Paclitaxel-Eluting Stent in Patients with De Novo Coronary Lesions: Three-Year Follow-up from the ENDEAVOR IV Trial

📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 228 KB

A Randomized Comparison of the Endeavor

A Randomized Comparison of the Endeavor Zotarolimus-Eluting Stent Versus the TAXUS Paclitaxel-Eluting Stent in De Novo Native Coronary Lesions: 12-Month Outcomes From the ENDEAVOR IV Trial

✍ Martin B. Leon; Laura Mauri; Jeffrey J. Popma; Donald E. Cutlip; Eugenia Nikolsk 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 923 KB

A RANDOMIZED COMPARISON OF THE ENDEAVOR

A RANDOMIZED COMPARISON OF THE ENDEAVOR DRUG (ABT-578) ELUTING STENT VERSUS TAXUS PACLITAXEL-ELUTING STENT IN DIABETIC PATIENTS: THREE-YEAR OUTCOMES FROM ENDEAVOR IV

✍ Kirtane, Ajay; Patel, Rikesh; O'Shaunessy, Charles; McLaurin, Brent; Kandzari, D 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 101 KB